The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting
FDG-PET-CT performed before cyclin-dependent kinase 4/6 inhibitor commencement is a valuable prognostic tool in hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. Patients with SUVmax less than 8.4 experienced extended progression-free survival compared to those with higher SUVmax.
Authors
- Sławomir Blamek (ORCID: https://orcid.org/0000-0002-0585-9100)
- K Swiderska
- Ewa Chmielik (ORCID: https://orcid.org/0000-0001-8316-0541)
- Michał Jarząb (ORCID: https://orcid.org/0000-0002-2642-9724)
- Andrea d’Amico (ORCID: https://orcid.org/0000-0003-4632-2139)
- Daria Handkiewicz-Junak (ORCID: https://orcid.org/0000-0003-0802-2880)
- Marcin Kubeczko (ORCID: https://orcid.org/0000-0003-1877-5691)
- Anna Polakiewicz-Gilowska (ORCID: https://orcid.org/0000-0002-2175-7067)
- Olgierd Chrabański (ORCID: https://orcid.org/0000-0003-1627-0614)
Institutions
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3389/fonc.2024.1454844
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.68